



**LESOTHO – PNEUMOCOCCAL VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

|  |       |             |             |             |                    |
|--|-------|-------------|-------------|-------------|--------------------|
| <b>1. Country:</b> Lesotho   |       |             |             |             |                    |
| <b>2. Grant Number:</b> 1216-LSO-12c-X / 12-LSO-08a-Y  |       |             |             |             |                    |
| <b>3. Date of Decision Letter :</b> 17 October 2013  |       |             |             |             |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 14 June 2013  |       |             |             |             |                    |
| <b>5. Programme Title:</b> New Vaccine Support   |       |             |             |             |                    |
| <b>6. Vaccine type:</b> Pneumococcal   |       |             |             |             |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID |       |             |             |             |                    |
| <b>8. Programme Duration<sup>1</sup>:</b> 2014 -2016   |       |             |             |             |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>                 |       |             |             |             |                    |
|  | 2013  | 2014        | 2015        | 2016        | Total <sup>2</sup> |
| Programme Budget (US\$)  | US\$0 | US\$619,000 | US\$908,000 | US\$535,000 | US\$2,062,000      |
| <b>10. Vaccine Introduction Grant:</b> US\$100,000 payable in 2014   |       |             |             |             |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement)<sup>3</sup>:</b>        |       |             |             |             |                    |
| Type of supplies to be purchased with GAVI funds in each year  | 2013  | 2014        |             |             |                    |
| Number of Pneumococcal vaccines doses  | 0     | 117,300     |             |             |                    |
| Number of AD syringes  | 0     | 124,100     |             |             |                    |
| Number of safety boxes   | 0     | 1,400       |             |             |                    |
| Annual Amounts (US\$)  | US\$0 | US\$619,000 |             |             |                    |
| <b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF.        |       |             |             |             |                    |
| <b>13. Self-procurement:</b> N/A   |       |             |             |             |                    |

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>3</sup> This is the amount that GAVI has approved.

**14. Co-financing obligations: Reference code:** 1216-LSO-12c-X-C - According to the Co-Financing Policy, the Country falls within the Intermediate Income group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2014       | 2015       | 2016       |
|--|------------|------------|------------|
| Number of vaccine doses  | 7,900      | 12,700     | 13,200     |
| Number of AD syringes  | 8,400      |            |            |
| Number of safety boxes   | 100        |            |            |
| Value of vaccine doses (US\$)                                    | US\$26,684 |            |            |
| Total Co-Financing Payments (US\$) (including freight)           | US\$29,000 | US\$46,000 | US\$48,000 |

**15. Operational support for campaigns:** N/A

|                     | 2014 | 2015 |
|---------------------|------|------|
| Grant amount (US\$) |      |      |

**16. Additional documents to be delivered for future disbursements:**

| Reports, documents and other deliverables | Due dates   |
|---|-------------|
| Annual Progress Report                    | 15 May 2014 |

**17. Financial Clarifications:** N/A

**18. Other conditions:** N/A

Signed by,

*Hind A. Khatib*

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2013

**LESOTHO – PENTAVALENT VACCINE SUPPORT**  
**This Decision Letter sets out the Programme Terms of a Programme**

|   |                            |             |             |                    |
|---|----------------------------|-------------|-------------|--------------------|
| <b>1. Country:</b> Lesotho  |                            |             |             |                    |
| <b>2. Grant Number:</b> 1215-LSO-04a-X  |                            |             |             |                    |
| <b>3. Date of Decision Letter :</b> 17 October 2013   |                            |             |             |                    |
| <b>4. Date of the Partnership Framework Agreement:</b> 14 June 2013   |                            |             |             |                    |
| <b>5. Programme Title:</b> New Vaccine Support  |                            |             |             |                    |
| <b>6. Vaccine type:</b> Pentavalent   |                            |             |             |                    |
| <b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 1 dose(s) per vial, LIQUID   |                            |             |             |                    |
| <b>8. Programme Duration<sup>4</sup>:</b> 2008 - 2015   |                            |             |             |                    |
| <b>9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):</b>          |                            |             |             |                    |
|   | 2008-2013                  | 2014        | 2015        | Total <sup>5</sup> |
| Programme Budget (US\$)   | US\$1,934,356 <sup>6</sup> | US\$314,000 | US\$242,500 | US\$2,490,856      |
| <b>10. Vaccine Introduction Grant:</b> N/A  |                            |             |             |                    |
| <b>11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement)<sup>7</sup>:</b> |                            |             |             |                    |
| Type of supplies to be purchased with GAVI funds in each year   | 2008-2013                  | 2014        |             |                    |
| Number of Pentavalent vaccines doses  |                            |             | 141,900     |                    |
| Number of AD syringes   |                            |             | 151,200     |                    |
| Number of safety boxes  |                            |             | 1,700       |                    |
| Annual Amounts (US\$)   | US\$1,934,356 <sup>8</sup> | US\$314,000 |             |                    |
| <b>12. Procurement agency:</b> UNICEF. The Country shall release its Co-Financing Payments each year to UNICEF. |                            |             |             |                    |
| <b>13. Self-procurement:</b> N/A  |                            |             |             |                    |

<sup>4</sup> This is the entire duration of the programme.

<sup>5</sup> This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table.

<sup>6</sup> This is the consolidated amount for all previous years.

<sup>7</sup> This is the amount that GAVI has approved.

<sup>8</sup> This is the consolidated amount for all previously approved years.

**14. Co-financing obligations: Reference code:** 1215-LSO-04a-X-C - According to the Co-Financing Policy, the Country falls within the Intermediate Income group. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2014        | 2015        |
|--|-------------|-------------|
| Number of vaccine doses  | 60,400      | 57,900      |
| Number of AD syringes  | 64,400      |             |
| Number of safety boxes   | 725         |             |
| Value of vaccine doses (US\$)                                    | US\$117,625 |             |
| Total Co-Financing Payments (US\$) (including freight)           | US\$133,500 | US\$128,000 |

**15. Operational support for campaigns:** N/A

|                     | 2014 | 2015 |
|---------------------|------|------|
| Grant amount (US\$) |      |      |

**16. Additional documents to be delivered for future disbursements:**

| Reports, documents and other deliverables | Due dates   |
|---|-------------|
| Annual Progress Report                    | 15 May 2014 |

**17. Financial Clarifications:** N/A

**18. Other conditions:** N/A

Signed by,

*Hind A. Khatib*

**On behalf of the GAVI Alliance**

Hind Khatib-Othman

Managing Director, Country Programmes

17 October 2013